Mucormycetes, mucor in short, is a ubiquitous fungus which thrives in soil, decaying organic matter and animal dung. The second point of conjecture is what has actually caused the huge surge in cases in India during the second wave of the COVID-19 pandemic. Hence, calling it correctly as mucormycosis or zygomycosis is the first step to understanding it. Treatment and prognosis varies by the diagnosis.
It is however important to know the difference because other types of fungus, albeit in lesser frequency, are also seen to infect COVID patients. This type of fungi is in fact non-pigmented when seen under the microscope. The blackness seen in mucormycosis affected patients arises from dead tissue caused by the ability of this fungus to invade blood vessels to eventually shut off distant blood supply. Though sensationalized by the media as “black fungus”, the medical community wouldn’t agree to this terminology for the root cause of this infection. For Assam, which is following the national capital by about two weeks in the health crisis, having reported a similar figure of 5000 cases daily last week, the time to be wary is now. Similar cases were soon reported in Maharashtra and Gujarat and by the end of the month the Indian Council of Medical Research (ICMR) had declared it as a notifiable disease. While the COVID-19 peak was declining for the better, the city saw an increase in cases of a rare fungal infection named mucormycosis, frequently occurring in patients who had previously recovered from COVID-19 infection. (This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.Delhi witnessed a new problem by mid May. Previously, she was working with ANZ Grindlays Bank PLC and Deutsche Bank AG, it added. Kaul holds a post-graduate diploma in management from the Indian Institute of Management, Ahmedabad. Previously, he was a Senior Partner at McKinsey & Company, Inc, the statement said.
He brings more than 28 years of global management consulting experience. Gupta holds a bachelor's degree from the Indian Institute of Technology, Delhi and a master's degree in Business Administration from Leland Stanford Junior University. I am confident that their broad-based expertise and strategic insights will continue to add great value to our Board and operations,'' Healthium Medtech CEO and MD Anish Bafna said. “Their depth of experience is exceptional. ''We are delighted to welcome Mr Ajay Gupta in his new role as the Chairman of our Board and Ms Namrata Kaul to our Board.
The appointments will also strengthen governance, and leverage a wealth of industry knowledge to help the company achieve its vision and strategic goals, it added. Healthium Medtech on Wednesday said it has elevated Ajay Gupta as Chairman of the Board and appointed Namrata Kaul as an independent member.Īs the company strengthens and expands its presence, Gupta and Kaul along with the other board of directors will continue to guide it to achieve profitable growth and provide surgeons and patients globally with cost-effective and high-quality medical devices, Healthium Medtech said in a statement.
0 kommentar(er)
